TMCI · CIK 0001630627 · operating
Treace Medical Concepts designs, manufactures, and markets surgical devices for the correction of bunion and related midfoot deformities. The company's primary product is the Lapiplasty 3D bunion correction system, which combines instruments and implants to address bunion deformity across three anatomical planes while stabilizing the underlying joint. The company also offers the Lapiplasty mini-incision system, enabling the procedure through a reduced 3.5-centimeter incision, and the Adductoplasty system for correction of metatarsus adductus deformities and midfoot osteoarthritis.
The company distributes its products primarily through direct sales to foot and ankle surgeons, as well as to ambulatory surgery centers and hospitals across the United States. Treace operates a single business segment focused on surgical devices for midfoot pathology management.
Treace Medical Concepts maintains 477 full-time employees and is based in Ponte Vedra, Florida. The company was founded in 2013 and is incorporated in Florida. As of the most recent reporting period, the company has a market capitalization of approximately $100 million and trades on Nasdaq.
Fiscal years are as reported by the company and may not align with the calendar year. For example, Apple's FY 2024 ends in September 2024.
| Fiscal Year | EPS Diluted | EPS Basic | YoY | |
|---|---|---|---|---|
| 2025 | $-0.93 | $-0.93 | -3.3% | |
| 2024 | $-0.90 | $-0.90 | -11.1% | |
| 2023 | $-0.81 | $-0.81 | -5.2% | |
| 2022 | $-0.77 | $-0.77 | — | |
| 2021 | — | — | — |